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Purpose/Objective: Range uncertainties in proton therapy 
can be reduced using in-vivo range verification based on 
prompt gamma (PG) imaging. In pencil beam scanning, PG 
emission can be measured for all pencil beams of the 
treatment and compared to the treatment planning in order 
to detect potential range discrepancies. This study proposes 
a strategy to analyze the large amount of PG profiles 
acquired during treatment using a priori simulations. 
Materials and Methods: Pencil beam scanning treatments 
were planned on an anthropomorphic phantom. Brain, nasal 
cavity and lung cases were included in the study. The 
treatments were delivered to the anthropomorphic phantom 
at the Proton Therapy Center in Prague, and PG monitoring 
was performed using a knife-edge slit gamma camera. Both 
single fraction (2 Gy) and full treatment at once (60 Gy) were 
delivered and measured. A dedicated analytical PG simulator 
was used to compute the expected PG profiles for all pencil 
beams of the treatment in the planning configuration. 
Several scenarios, corresponding to several possible sources 
of range discrepancy (i.e. setup errors, CT calibration errors 
and energy errors), were simulated as well. The 
corresponding range shifts were computed based on CSDA 
approximation in order to estimate the range sensitivity. 
Moreover, the range shifts were estimated from the 
simulated profiles using a range retrieval method. The 
difference between CSDA-based shifts and shifts estimated 
from the simulated PG profiles defined the expected 
systematic error in range retrieval for each pencil beam. The 
actual range was then estimated based on the comparison of 
measured and simulated profiles. The range shifts were also 
retrieved from the comparison of 2 Gy and 60 Gy acquisitions 
in order to evaluate an occurrence of the random errors. In 
order to improve range assessment, a selection of the most 
reliable pencil beams was done based on weight and 
expected systematic errors. 
Results: Realistic treatments were successfully delivered to 
an anthropomorphic phantom and monitored using the PG 
camera. Using all pencil beams, the average systematic range 
shift extracted from the comparison of the 60 Gy acquisition 
with the simulation were of 4.1, 5.8 and -4.0 mm for brain, 
nasal cavity and lung, respectively. The average random 
error was of 2.4, 4.5 and 2.2 mm. When selecting the pencil 
beams whose weight was higher than 0.3 MUs and whose 
systematic error was smaller than 1 mm, the systematic 
range shift was 4.1, 6.8 and -3.2, and the random errors went 
down to 1.6, 1.9 and 2.2 mm. 
 
 
 
Figure: Treatment plan (top-left), experimental setup (top-
right), and range analysis on first energy layer (bottom): (a) 
range sensitivity to energy variations of +/- 3 MeV on first 
layer; (b) systematic error on range retrieval for energy 
variations; (c) range shifts from 60 Gy acquisition; (d) range 
shifts from 2 Gy acquisition. The size of the spots is 
proportional to their weight. 
Conclusions: The first prompt gamma-based range 
monitoring of realistic proton pencil beam scanning 
treatments on an anthropomorphic phantom were 
successfully conducted and a strategy to extract range 
discrepancies was proposed.  
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Purpose/Objective: Radiochromic 3D dosimetry has great 
potential for verification of complex treatment techniques 
such as adaptive radiotherapy and proton therapy. However, 
the response to irradiation is often dependent on dose-rate, 
which can limit their use in clinical environments. Recently, 
we have developed a radiochromic silicone-based 3D 
dosimeter, where the first generation of the dosimeter had 
an issue with dose-rate dependency. However, by changing 
the chemical composition of the dosimeter, we have in this 
study reduced the dose-rate dependence to a clinically 
acceptable level. 
Materials and Methods: The silicone-based dosimeters were 
produced by mixing leuco-malachite green (LMG) dye as the 
active component, 1 % (w/w) chloroform as the initiator and 
a silicone elastomer as the host matrix. All dosimeters were 
left to cure for two days at room temperature. Thereafter 
they were irradiated with a linac to doses in the range 0-30 
Gy, in a 10 cm square field and with a beam quality of 6 MV. 
During irradiation they were placed at SSD 94.5 cm between 
two 5 cm slabs of solid water. Experiments were performed 
at dose-rates of 200 MU/min and 600 MU/min for a series of 
dosimeters with different LMG concentrations. The 
dosimeters were then read-out using a spectrophotometer at 
627 nm before and after irradiation to obtain the change in 
optical density (Δ OD) caused by the irradiation. Δ OD was 
plotted as a function of dose and fitted to a linear expression 
with the slope giving the dose response. The dose-rate 
dependence was then expressed as the percentage difference 
between the dose responses of the two dose-rate 
measurements, relative to the 200 MU/min measurement. 
Results: The dose-rate dependence was greatly reduced with 
increasing dye concentration (Figure). Below 0.05 % (w/w) 
LMG it was observed to be around 17 %, while it was 
eliminated in dosimeters containing 0.25 % (w/w) LMG. For 
higher dye concentrations the dose-rate dependence was 
reversed. Similar observations were made for dosimeters with 
5 % (w/w) chloroform. 
The stability of the dosimeters was found to decrease linearly 
with increasing LMG concentration, with a 50 % decrease 
within a day for a concentration of 0.2 % (w/w) LMG. In 
addition, at the highest concentrations precipitation was 
observed within days to weeks after production. 
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Conclusions: This study shows that the radiochromic silicone 
based 3D dosimeter is dose-rate independent with 0.25 % 
(w/w) LMG and 1 % (w/w) chloroform. This greatly enhances 
its usability in clinical environments, however, the decreased 
stability of the dosimeter due to the increased LMG 
concentration must be carefully considered. 
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Purpose/Objective: The new DMI MV imaging panel with 
Eclipse/Aria permits measurements of FFF integrated images 
and configuration of the Portal Dosimetry algorithm ('PDIP') 
for QA of IMRT and Rapid Arc ('RA') treatment plans. This 
study evaluates the commissioning procedure for the Portal 
Dosimetry ('PD') system for FFF energies and the resulting 
implementation for IMRT and RA pre-treatment QA. To 
evaluate the accuracy and performance of the PD system, 
measurements were also performed using the new Octavius 
1500 system.  
Materials and Methods: A Varian TrueBeam equipped with 
HD-MLC and the new DMI imager was used to configure and 
evaluate the PDIP algorithm. The DMI panel has high 
resolution imaging capabilities and together with the new 
version of Eclipse/Aria (V.13) allows for configuration of the 
PDIP for use with FFF energies. The PDIP was configured for 
use at 100 cm SDD by measuring the imager output factors 
and an ideal fluence provided by Varian. The 6 MV was used 
as the standard for performance evaluation of the imager and 
PD configuration for the 6 and 10 FFF energies. Measured 
output factors, open fields, and test complex fluences were 
compared to those predicted by the PDIP to validate the 
configuration. Test IMRT and RA plans were measured and 
analyzed using the PD software. A further evaluation of the 
PD was performed by repeating fluence and test plan 
measurements on the new Octavius 1500 array system. The 
array was commissioned with solid water plates and also 
inserted in the cylindrical rotational polystyrene phantom 
(Octavius 4D). The latter setup was used with an inclinometer 
to assess the agreement between measured and planned 
doses and for comparison with results obtained on the PD. 
Volumetric (3D) and planar (2D) gamma analysis are available 
for the reconstructed dose volume to check the dose in a 
volume or in a plane, respectively. All fluences and test plans 
were analyzed using the gamma criteria of 2%-2mm and 10% 
dose threshold. 
Results: The PDIP algorithm showed agreement within <1% 
between the measured and calculated output factors for 6 
MV and 6 FFF and within <1.5% for 10 FFF. The open field and 
test fluences on the PD system resulted in a gamma passing 
criteria >99.0% and >97.2%, respectively. The test IMRT plans 
resulted in gamma analysis >99.2% (<γ>=99.7±0.4%) on the 
PD, >96.5% (<γ>=98.0±1.6%) on the Octavius with 2D analysis, 
and >97.1% (<γ>=97.5±0.5%) on the Octavius with 3D analysis. 
The test RA plans resulted in a gamma analysis >97.0% 
(<γ>=99.0±1.2%) on the PD and >97.8% (<γ>=99.0±0.7%) on 
the Octavius with 3D analysis (Figure: 10FFF RA;Table: RA 
analysis).  
 
 
Conclusions: The Portal Dosimetry system for the TrueBeam 
with DMI imager can be used for IMRT and RA pretreatment 
QA verification for FFF energies. The results obtained with 
the PD were comparable to those obtained with direct 
measurement equipment such as the PTW Octavius 1500. The 
PD system has higher resolution and measurement points 
which could have resulted in a slightly higher gamma analysis 
passing rate when compared to the Octavius. 
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Purpose/Objective: This work evaluates the potential of the 
new aS1200 EPID (Varian Medical Systems) for pre-treatment 
and in vivo dosimetry (IVD) applications. 
Materials and Methods: Measurements were performed using 
one aS1200 and an older aS1000 unit, both mounted on 
matched TrueBeam linacs. Comparative specifications are in 
Table 1. 
